BMC Cancer最新文献

{"title":"Prognostic significance of CDK1 expression in diffuse large B-Cell lymphoma.","authors":"Qiuni Chen, Lei Xu, Chuanyang Lu, Yujie Xue, Xue Gong, Yuye Shi, Chunling Wang, Liang Yu","doi":"10.1186/s12885-024-13388-y","DOIUrl":"https://doi.org/10.1186/s12885-024-13388-y","url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adult, characterized by uncontrolled cell proliferation and strong aggressiveness. Previous studies have found that cyclin-dependent kinase 1(CDK1) are related to tumor growth and metastasis. However, the role of CDK1 in DLBCL is exclusive. This study investigated the clinical implications and expression of CDK1 in DLBCL.</p><p><strong>Methods: </strong>Gene expression data for healthy subjects were sourced from the Genotype-Tissue Expression repository. Clinical details and survival statistics of patients with DLBCL were obtained from the Gene Expression Omnibus archive (GSE10846). Patients were categorized based on CDK1 expression levels, and differences in clinical outcomes between the groups were examined. Univariate and multivariate Cox regression analyses were used to ascertain whether CDK1 expression independently predicted DLBCL prognosis. The protein expression of CDK1 was gauged by immunohistochemistry. Additionally, we investigated the effect of CDK1 inhibition on DLBCL cell growth and death using the Cell Counting Kit-8 and flow cytometry.</p><p><strong>Results: </strong>In the control group, CDK1 expression was predominantly observed in the hematopoietic and reproductive systems. CDK1 levels in patients with DLBCL were notably elevated compared with those in controls. Significant differences were noted in the lactate dehydrogenase ratio and overall survival based on CDK1 expression. Statistical analyses confirmed that CDK1 was an independent predictor of DLBCL outcomes. Elevated CDK1 protein levels were observed in a significant number of DLBCL samples, in contrast to normal lymph node samples from individuals without lymphoma. The inhibitor Ro-3306 curtails DLBCL cell growth and enhances cell death in vitro.</p><p><strong>Conclusions: </strong>Elevated CDK1 levels are correlated with poor prognosis in patients with DLBCL.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"20"},"PeriodicalIF":3.4,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highly proliferating cancer cells function as novel prognostic biomarkers for lung adenocarcinoma with particular usefulness for stage IA risk stratification.","authors":"Yanlu Xiong, Yongfu Ma, Jie Lei, Jianfei Zhu, Nianlin Xie, Feng Tian, Qiang Lu, Miaomiao Wen, Qian Zheng, Yong Han, Tao Jiang, Yang Liu","doi":"10.1186/s12885-024-13308-0","DOIUrl":"https://doi.org/10.1186/s12885-024-13308-0","url":null,"abstract":"<p><strong>Background: </strong>The refinement of risk stratification in lung adenocarcinoma (LUAD) plays a pivotal role in advancing precision medicine; however, the current staging classification falls short of comprehensiveness, particularly in the case of stage IA patients. We aimed to molecularly stratify LUAD patients especially for stage IA.</p><p><strong>Methods: </strong>We analysed tumour heterogeneity and identified highly proliferating cancer cells (HPCs) in LUAD by performing single-cell RNA sequencing (scRNA-seq) analysis, immunohistochemical (IHC) staining using a tissue microarray, flow cytometry and biological experiments. Then, we quantified the content of HPCs in nine LUAD datasets by single-sample gene set enrichment analysis and evaluated the relationship between the percentage of HPCs and overall survival (OS). Next, we analysed the OS predictive effect of HPCs at different LUAD stages, especially for stage I risk stratification. Furthermore, we established a prognostic prediction model based on HPC-associated genes for clinical application. The above findings were validated in another five LUAD datasets. Finally, we explored the relationship between HPCs and the progressive pathological evolution of early-stage LUAD and the driving mutations by scRNA-seq, bulk RNA-seq and IHC staining.</p><p><strong>Results: </strong>LUAD tissues carry a small proportion of HPCs, which show potential for malignant proliferation and intense interactions with the microenvironment. A high HPC content is an independent risk factor for OS in LUAD patients, even in stage IA patients. HPCs can be used to establish a cut-off point for the prognosis of stage IA disease, with patients with a higher risk showing a prognosis similar to that of patients with stage IB disease. We built an R package (HSurADs) based on HPC-associated genes, which exhibited good efficacy for the prognostic prediction of LUAD. HPCs gradually increase with the pathological evolution of early-stage LUAD, which may be affected by TP53 mutations.</p><p><strong>Conclusion: </strong>The HPC content can be used as a novel prognostic factor for LUAD, especially for stage IA risk stratification.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"25"},"PeriodicalIF":3.4,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between METTL3 overexpression and ¹⁸F-FDG uptake in patients with soft tissue sarcoma.","authors":"Tong Wu, Jinghui Xie, Hongbo Feng, Hua Zhang, Juan Tao, Bo Chen","doi":"10.1186/s12885-024-13419-8","DOIUrl":"https://doi.org/10.1186/s12885-024-13419-8","url":null,"abstract":"<p><strong>Background: </strong>N6-methyladenosine (m6A) methylation plays a key role in tumor progression. However, the significance of methyltransferase-like 3 (METTL3) in biological processes of soft tissue sarcoma (STS) patients, and the relationship between METTL3 and STS are unclear.</p><p><strong>Methods: </strong>The expression of METTL3 in STS and its relationship with patient prognosis were determined from database analyses. Immunohistochemical staining and ¹⁸F-FDG radioautography were performed on tumor tissues from 39 patients with STS undergoing ¹⁸F-FDG PET before treatment. METTL3 expression in tumor and peritumoral tissues was evaluated with the Wilcoxon test. The Mann-Whitney U test and Spearman's correlation analysis were used to explore correlations of METTL3 expression with both clinicopathological characteristics and ¹⁸F-FDG uptake. One-way analysis of variance and ROC analysis were used to evaluate the efficacy of ¹⁸F-FDG PET metabolic parameters in predicting METTL3 expression.</p><p><strong>Results: </strong>METTL3 expression was significantly higher in STS tumor tissues than normal tissues (all p values<0.01), and correlated with poor patient prognosis (p < 0.05). METTL3 expression was associated with histological differentiation (Z=-2.026, p = 0.043), but no significant difference was observed according to age, sex, tumor size, tumor location, or metastasis (all p values > 0.05). METTL3 expression positively correlated with the expression of CD163 (r = 0.502, p = 0.011), CD68 (r = 0.381, p = 0.017), and CD8 (r = 0.319, p = 0.048), and exhibited a trend toward correlation with CD4 expression (r = 0.310, p = 0.055). Moreover, ¹⁸F-FDG metabolism positively correlated with METTL3 expression in STS (r = 0.580 for PET and r = 0.434 for radioautography, all p values<0.01). The SUVmax of PET was significantly higher in tumors with high rather than low METTL3 expression (Z=-2.979, p = 0.003).</p><p><strong>Conclusions: </strong>METTL3 was overexpressed in STS, which may be a meaningful target of action in STS patients. The ¹⁸F-FDG uptake was significantly elevated in tumors with high METTL3 expression, SUVmax could provide a meaningful imaging biomarker for its expression.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"27"},"PeriodicalIF":3.4,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11708263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting.","authors":"Lu Sun, Jia Ma, Yajuan Zhou, Xiaofang Ying, Gai Liang, Guoliang Pi, Ying Li, Yan Luo, Jianping Bi, Hanping He, Yi Peng","doi":"10.1186/s12885-024-13406-z","DOIUrl":"https://doi.org/10.1186/s12885-024-13406-z","url":null,"abstract":"<p><strong>Objective: </strong>Ondansetron orally soluble pellicle can serve as an alternative option for preventing nausea and vomiting in patients who receive chemotherapy. However, there is a lack of clinical evidence regarding ondansetron. This study aimed to explore the efficacy and safety of ondansetron in patients with malignant tumours who received chemotherapy drugs with a moderate-to-high emetic risk.</p><p><strong>Methods: </strong>In total, 163 patients with malignant tumours received 24 mg of ondansetron via orally soluble pellicles at 30 min before chemotherapy (8 mg each time for three consecutive administrations). The incidence rates of nausea and vomiting in the three days after chemotherapy were recorded.</p><p><strong>Results: </strong>Regarding the effect of ondansetron on vomiting, the complete response (zero episodes of vomiting), major response (1-2 episodes of vomiting), minor response (3-5 episodes of vomiting), and failure (> 5 episodes of vomiting) rates were 96.9%, 1.2%, 1.2%, and 0%, respectively. The major efficacy rate for vomiting (complete response + major response rates) was 98.1%. Moreover, 96.3% of patients did not experience nausea, 2.5% of patients experienced mild nausea, 1.2% of patients experienced moderate nausea, and 0.0% of patients experienced severe nausea. The major efficacy rate for nausea (no nausea) was 96.3%. Age > 65 years was negatively associated with major efficacy for vomiting, and a chemotherapy regimen involving cisplatin was negatively associated with major efficacy for nausea. A total of 42 (25.8%) patients experienced adverse events. The most common adverse events were elevated levels of alanine transaminase (6.7%), elevated levels of aspartate transaminase (3.7%), fatigue (3.7%), and cough (2.5%).</p><p><strong>Conclusion: </strong>Ondansetron orally soluble pellicle shows good antiemetic efficacy and high safety in patients with malignant tumours who receive chemotherapy drugs with a moderate-to-high emetic risk.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"16"},"PeriodicalIF":3.4,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of mediastinoscopy and thoracoscope minimally invasive esophagectomy in the treatment of esophageal cancer: a meta-analysis and system review.","authors":"Jincheng Wang, Linxian Zhao, Jie Lin, Yating Yu, Ti Tong, Yinghao Zhao","doi":"10.1186/s12885-024-13307-1","DOIUrl":"https://doi.org/10.1186/s12885-024-13307-1","url":null,"abstract":"<p><strong>Objective: </strong>The efficacy and safety of transcervical inflatable mediastinoscopic esophagectomy (TIME) in the treatment of esophageal cancer are unclear. The objective of this meta-analysis was to evaluate the efficacy and safety of TIME treatment for esophageal cancer and to compare it with thoracoscopic assisted minimally invasive esophagectomy (TAMIE) for the treatment of esophageal cancer.</p><p><strong>Methods: </strong>A literature search was performed using PubMed, Embase, and the Cochrane Library to retrieve articles published up to January 2024 to comparatively assess studies of TIME and TAMIE. Meta-analysis was performed using randomized/fixed-effects models and heterogeneity was assessed.</p><p><strong>Results: </strong>A total of 819 patients were included in the nine studies herein. Among them, 409 patients with esophageal cancer underwent mediastinoscopy-assisted esophagectomy, and 410 patients with esophageal cancer underwent thoracolaparoscopy-assisted esophagectomy. There was no statistical difference between the TIME and TAMIE groups in intraoperative bleeding, incidence of anastomotic fistula, chylothorax, postoperative bleeding, arrhythmia, postoperative complications and in-hospital mortality. In addition, the operative time in the TIME group, 3-day postoperative induced flux, postoperative hospitalization time, number of lymph node dissection, and incidence of pulmonary complications were smaller than those in the TAMIE group, and the differences were all statistically significant. However, in terms of the incidence of recurrent laryngeal nerve injury (including hoarseness), the TIME group was higher than the TAMIE group.</p><p><strong>Conclusion: </strong>TIME is a safe and feasible alternative to TAMIE for the treatment of resectable esophageal cancer, but further randomized studies are needed to better assess the long-term benefits of TIME compared with TAMIE.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"14"},"PeriodicalIF":3.4,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11702258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer patterns by age groups in Brazil: insights from population-based registries data.","authors":"Jessé Lopes da Silva, Luiz Claudio Santos Thuler, Andréia Cristina de Melo","doi":"10.1186/s12885-024-13381-5","DOIUrl":"https://doi.org/10.1186/s12885-024-13381-5","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) has exhibited varied epidemiological trends based on distinct age categories. This research aimed to explore the incidence and mortality rates of BC within pre-defined age groups in the Brazilian population.</p><p><strong>Methods: </strong>BC incidence trends were assessed from 2010 to 2015 using Brazilian Population-Based Cancer Registries, employing age-standardized ratios and annual average percentage change (AAPC). Hospital-Based Cancer Registries provided clinical and sociodemographic data from 2000 to 2019. Mortality data were obtained from the National Mortality Information System from 2000 to 2020. Three groups were compared: < 40, 40-69, and ≥ 70 years.</p><p><strong>Results: </strong>From 2010 to 2015, 205,966 new BC cases were recorded, with incidence rates of 7.1/100,000 for < 40, 156.5/100,000 for 40-69, and 247.5/100,000 for ≥ 70 years. The < 40 years group exhibited a significant increase in incidence rate (AAPC + 1.6; 95% CI: 1.0 to 2.2; p < 0.001). This age group also showed a higher proportion of black patients (53%, p < 0.001), alcohol consumption (20.5%, p < 0.001), proportion of patients treated at stages ≥ IIB (64.0%, p < 0.001), and a higher likelihood of receiving multiple treatment modalities (60.7%, p < 0.001). The ≥ 70 years group experienced a longer delay exceeding 60 days from diagnosis to treatment onset (54%, p < 0.001), while exhibiting a higher proportion of endocrine therapy utilization (45.3%, p < 0.01). Mortality rates increased across all subgroups, with the < 40 years group showing the most pronounced increase (AAPC + 1.8%; 95% CI: 1.6 to 2.1; p < 0.001).</p><p><strong>Conclusion: </strong>These results highlight marked disparities in BC incidence, mortality rates, clinicopathological and sociodemographic characteristics between women under 40, and those in the 40-69 and ≥ 70 age groups in Brazil.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"18"},"PeriodicalIF":3.4,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of a mitophagy-related gene signature for predicting overall survival and response to immunotherapy in rectal cancer.","authors":"Jian Yang, Zhifei Cao, Chengqing Yu, Wenxu Cui, Jian Zhou","doi":"10.1186/s12885-024-13412-1","DOIUrl":"https://doi.org/10.1186/s12885-024-13412-1","url":null,"abstract":"<p><strong>Background: </strong>Rectal cancer is a highly heterogeneous gastrointestinal tumor, and the prognosis for patients with treatment-resistant and metastatic rectal cancer remains poor. Mitophagy, a type of selective autophagy that targets mitochondria, plays a role in promoting or inhibiting tumors; however, the importance of mitophagy-related genes (MRGs) in the prognosis and treatment of rectal cancer is unclear.</p><p><strong>Methods: </strong>In this study, we used the differentially expressed genes (DEGs) and MRGs from the TCGA-READ dataset to identify differentially expressed mitophagy-related genes (MRDEGs). The mitophagy scores were then analyzed for differential expression and ROC. Seven module genes were identified using the weighted gene coexpression network analysis (WGCNA) approach and subsequently validated in the merged datasets GSE87211 and GSE90627. The model genes were obtained based on prognostic features, and the subgroups were distinguished by risk score. Gene enrichment, immune infiltration and immunotherapy response were also evaluated. Finally, validation of prognostic gene expression in rectal cancer was carried out using clinical samples, employing Immunohistochemistry (IHC).</p><p><strong>Results: </strong>We demonstrated that 22 MRGs were differentially expressed between normal and rectal cancer tissues. A prognostic model for rectal cancer MRGs was constructed using WGCNA and Cox regression, which exhibited good diagnostic performance. In this study, we identified four molecular markers (MYLK, FLNC, MYH11, and NEXN) as potential prognostic biomarkers for rectal cancer for the first time. Moreover, our findings indicate that the risk scores derived from the four MRGs are associated with tumor immunity. To further validate our findings, IHC analyses suggested that the expression of MYH11 in rectal cancer tissues was lower than in nontumorous rectal tissues.</p><p><strong>Conclusion: </strong>MRGs could predict the prognosis and response to immunotherapy in patients with rectal cancer and might be able to personalize treatment for patients.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"15"},"PeriodicalIF":3.4,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sedated and unsedated gastroscopy has no influence on the outcomes of patients with gastric cancer: a retrospective study.","authors":"Chengke Yin, Yiwu Sun, Jie Liang, Xin Sui, Zhaoyi He, Ailing Song, Wenjia Xu, Lei Zhang, Yufei Sun, Jingshun Zhao, Fei Han","doi":"10.1186/s12885-024-13413-0","DOIUrl":"https://doi.org/10.1186/s12885-024-13413-0","url":null,"abstract":"<p><strong>Background: </strong>Different anesthetic drugs and techniques may affect survival outcomes for gastric cancer (GC) after surgery. In this study, we investigated the association between sedated and unsedated gastroscopy on survival outcomes in patients with GC after surgery.</p><p><strong>Methods: </strong>This was a retrospective study of patients who were diagnosed with GC by gastroscopy and underwent gastrectomy from January 2013 to December 2017. They were grouped based on the examination modality: propofol-based sedated gastroscopy or unsedated gastroscopy. Propensity score matching (PSM) was used to balance the baseline variables. Survival outcomes and distant metastases were compared between these two groups.</p><p><strong>Results: </strong>Finally, 673 patients were enrolled, 160 in the sedated gastroscopy group and 513 in the unsedated gastroscopy group. After PSM, there were 160 patients in each group. There was no significant difference in overall survival outcomes in the sedated gastroscopy group compared to the unsedated gastroscopy group before PSM (HR = 0.761, 95% CI: 0.531-1.091, P = 0.139) or after PSM (HR = 0.874, 95% CI: 0.564-1.355, P = 0.547). There was no significant difference in the incidence of distant metastases between the two groups before PSM (16.9% vs. 20.7%, P = 0.294) or after PSM (16.9% vs. 23.8%, P = 0.126). To confirm that our patients behaved similarly to other studies, we performed a multivariate analysis and the results showed that sex, pathological TNM stage, Borrmann type, adjuvant treatment, and surgical resection range were all independent factors affecting survival outcomes in our patients.</p><p><strong>Conclusion: </strong>Our results showed no significant difference in the effects of sedated gastroscopy vs. unsedated gastroscopy on survival outcomes or distant metastases of patients after gastrectomy for GC.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"13"},"PeriodicalIF":3.4,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11702075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors.","authors":"Yusuke Hamakawa, Ayumi Hirahara, Akiko Hayashi, Kota Ito, Hiroyuki Shinohara, Aya Shiba, Yuko Higashi, Masaharu Aga, Kazuhito Miyazaki, Yuri Taniguchi, Yuki Misumi, Yoko Agemi, Yukiko Nakamura, Tsuneo Shimokawa, Hiroaki Okamoto","doi":"10.1186/s12885-025-13440-5","DOIUrl":"https://doi.org/10.1186/s12885-025-13440-5","url":null,"abstract":"<p><strong>Introduction: </strong>The systemic immune-inflammation index (SII) has emerged as a promising prognostic marker in various malignancies. However, its prognostic significance in patients with small-cell lung cancer (SCLC) treated with immune checkpoint inhibitors (ICIs) remains unclear. In this study, we evaluated the prognostic impact of the SII in patients with SCLC after ICI use.</p><p><strong>Methods: </strong>Of 62 patients with SCLC who received chemoimmunotherapy at our institution between September 2019 and July 2024, we retrospectively analyzed 36 patients who subsequently received ICI maintenance therapy following the initial chemoimmunotherapy treatment. The SII was calculated at the start of the second cycle of the ICI maintenance therapy. Patients were stratified into high (≥ 570) and low (< 570) SII groups. Overall survival (OS) and progression-free survival (PFS) were compared between the groups using the Kaplan-Meier method and log-rank test. Multivariate analysis using the Cox proportional hazards model was performed to identify independent prognostic factors.</p><p><strong>Results: </strong>The high SII group exhibited a significantly shorter OS (median 12.1 vs. 24.1 months, P = 0.010) and PFS (median 5.2 vs. 8.1 months, P = 0.026) than those in the low SII group. A multivariate analysis identified SII ≥ 570 as an independent negative prognostic factor for OS (hazard ratio 3.83, 95% confidence interval 1.38-10.6, P = 0.010).</p><p><strong>Conclusions: </strong>Elevated SII in the initial phase of ICI maintenance therapy was associated a with poor prognosis in patients with SCLC, supporting its utility as a prognostic biomarker in this setting. Therefore, prospective validation is required to confirm these findings.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"17"},"PeriodicalIF":3.4,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular subtype of gastric cancer based on apoptosis-related genes reveals differential immune microenvironment and intratumoral microorganisms distribution.","authors":"Xuan Yu, Yongfu Shao, Haotian Dong, Jianing Yan, Xinjun Zhang, Guoliang Ye","doi":"10.1186/s12885-024-13411-2","DOIUrl":"https://doi.org/10.1186/s12885-024-13411-2","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is known for its high heterogeneity, presenting challenges in current clinical treatment strategies. Accurate subtyping and in-depth analysis of the molecular heterogeneity of GC at the molecular level are still not fully understood.</p><p><strong>Methods: </strong>This study categorized GC into two subtypes based on apoptosis-related genes (ARGs) and investigated differences in tumor immune microenvironment, intratumoral microorganisms distribution, gene expression, and signaling pathways. Key prognostic genes related to apoptosis in GC were identified through random survival forest analysis, and their specific signaling mechanisms were explored. Expression levels of key genes were validated through PCR in paired GC tissues and cancer cell lines. Moreover, biological functions of these key genes were verified in vitro experiments.</p><p><strong>Results: </strong>A consistent clustering of GC was conducted using 161 apoptosis-related genes (ARGs), resulting in the identification of two subtypes, C1 and C2. Subsequently, significant differences were found in the tumor immune microenvironment, intratumoral microorganisms, gene expression, signaling pathways, and protein interaction networks between the two subtypes. GPX3, PLAT, and CAV1 were identified as key prognostic genes related to apoptosis in GC, with a focus on their impact on disease progression-related pathways. Furthermore, PCR assays validated that these three key genes exhibited significantly low expression levels in both GC cell lines and tissues. Finally, knocking down key genes expression significantly promoted cell proliferation, colony formation and invasion of GC.</p><p><strong>Conclusions: </strong>Our study conducted a comprehensive analysis of the molecular characteristics of ARGs in GC, revealed their association with the tumor immune microenvironment and intratumoral microorganisms. These findings provide new ideas for the molecular classification of GC.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"12"},"PeriodicalIF":3.4,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11702164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}